RT Journal Article
SR Electronic
T1 Biomarkers of Inflammation and Progression During Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 393
OP 399
DO 10.21873/invivo.13091
VO 37
IS 1
A1 MARTINA SPISAROVA
A1 BOHUSLAV MELICHAR
A1 JARMILA JURANOVA
A1 ANEZKA ZEMANKOVA
A1 TOMAS ADAM
A1 KATERINA MATOUSOVA
A1 LENKA JAVORSKA
A1 LENKA KUJOVSKA KRCMOVA
A1 DOROTA TURONOVA
A1 HANA STUDENTOVA
YR 2023
UL http://iv.iiarjournals.org/content/37/1/393.abstract
AB Background/Aim: Biomarkers that would identify patients unlikely to respond to immunotherapy with immune checkpoint inhibitors (ICIs) remain an unmet medical need. Patients and Methods: In the present study, we have retrospectively evaluated the association between biomarkers of immune activation and outcome in metastatic renal cell carcinoma (mRCC) patients treated with ICIs. The laboratory and clinical data of 79 consecutive patients with histologically confirmed mRCC treated with ICI-based immunotherapy have been analyzed. Results: Patients who progressed or died at 4 months had higher prognostic score, higher serum C-reactive protein (CRP) and neopterin, and urinary neopterin, and lower serum albumin and hemoglobin concentration. Conclusion: Biomarkers of activation of immune response, in particular serum neopterin/creatinine ratio, are associated with outcome in mRCC patients treated with ICI immunotherapy.